Dermata Therapeutics (DRMA) Retained Earnings (2021 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Retained Earnings of $81.5 million for Q1 2026, up 8.26% year-over-year from $75.3 million in Q1 2025, and up 211.28% quarter-over-quarter from -$73.2 million in Q4 2025.
Dermata Therapeutics (DRMA) Retained Earnings (2021 - 2026) Analysis & Trends
Dermata Therapeutics' Retained Earnings history runs 6 years deep, the most recent figure standing at $81.5 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 8.26% year-over-year to $81.5 million; the TTM figure through Mar 2026 stood at $81.5 million (up 8.26% YoY), while the FY2025 annual figure was -$73.2 million, down 208.92% from the prior year.
- Retained Earnings for Q1 2026 stood at $81.5 million, up from -$73.2 million in the prior quarter.
- The five-year high for Retained Earnings was $81.5 million in Q1 2026, with the low at -$73.2 million in Q4 2025.
- The 5-year median for Retained Earnings is -$38.8 million (2022), against an average of $1.8 million.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 244.24% in 2023, then sank 208.92% in 2025.
- Dermata Therapeutics' Retained Earnings stood at $51.6 million in 2022, then sank by 203.43% to -$53.4 million in 2023, then soared by 225.94% to $67.2 million in 2024, then tumbled by 208.92% to -$73.2 million in 2025, then jumped by 211.28% to $81.5 million in 2026.
- Business Quant data shows DRMA's Retained Earnings at $81.5 million in Q1 2026, -$73.2 million in Q4 2025, and $75.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Dermata Therapeutics | 5.42 Mn | 5.42 Mn | - | 81.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.49 Mn |
| Dec 31, 2025 | -73.23 Mn |
| Sep 30, 2025 | 75.33 Mn |
| Jun 30, 2025 | -69.70 Mn |
| Mar 31, 2025 | 75.28 Mn |
| Dec 31, 2024 | 67.24 Mn |
| Sep 30, 2024 | -62.52 Mn |
| Jun 30, 2024 | -59.35 Mn |
| Mar 31, 2024 | 60.33 Mn |
| Dec 31, 2023 | -53.39 Mn |
| Sep 30, 2023 | -51.25 Mn |
| Jun 30, 2023 | 57.56 Mn |
| Mar 31, 2023 | 55.92 Mn |
| Dec 31, 2022 | 51.61 Mn |
| Sep 30, 2022 | -43.92 Mn |
| Jun 30, 2022 | -41.50 Mn |
| Mar 31, 2022 | -38.77 Mn |
| Dec 31, 2021 | 46.09 Mn |
| Sep 30, 2021 | -33.43 Mn |
| Jun 30, 2021 | -31.72 Mn |